SOURCE: Cytonics Corporation

Cytonics Corporation

March 17, 2015 10:00 ET

Cytonics Receives Approval for UK Patent Related to A2M for the Treatment of Musculoskeletal Disease

JUPITER, FL--(Marketwired - March 17, 2015) - Cytonics Corporation, a biotechnology company focused on proteomic-based diagnostics and treatments for musculoskeletal disease, announced today that the UK Patent Office has awarded a patent related to the use of the protein A2M as a therapeutic agent for treating a range of musculoskeletal diseases including osteoarthritis (OA). The patent number GB2501611 is titled "Alpha-2-Macroglobulin Compositions and Therapeutic Uses."

The company's research has been focused on developing novel protease inhibition therapeutics, which led to the discovery that A2M has the ability to inhibit all known proteases, including MMP's and ADAMTS's, that cause cartilage degeneration and that lead to osteoarthritis (OA). Cytonics also has shown significant therapeutic benefit of A2M in treating chronic wounds like Diabetic Foot Ulcers.

Αlpha-2-Macroglobulin (A2M) is a broad-spectrum multi-purpose protease inhibitor found in relatively high concentrations in blood (typically 1 to 2mg/ml). A2M is a trap-like protein with a central "bait region" which effectively attracts and binds to harmful proteases that cause cartilage breakdown and lead to OA. It also controls and regulates pro-inflammatory cytokines as well as growth factors through a binding mechanism.

The recently issued patent includes a very unique set of "composition of matter claims" related to the concentration of A2M by any method that results in more than a 1.1x concentration above the intrinsic amount in a patient's blood. The issued patent also includes a range of device and use claims related to the autologous concentration of A2M from a patient's own blood. This new patent further expands Cytonics' intellectual property portfolio protecting A2M as a therapeutic for musculoskeletal disease and for chronic wounds.

About Cytonics Corporation

Cytonics is a research and development company dedicated to discovering and developing therapeutics and diagnostics for musculoskeletal disease. The company has discovered a unique "bio-marker" that will allow physicians to improve patient outcomes by pinpointing the source of orthopedic pain. Cytonics has also developed a range of autologous and recombinant therapeutic products based on A2M for the treatment of painful osteoarthritis, back, and joint pain.

Contact Information